Earnings360 Newsletter for 6/20/2024

Earnings360 Newsletter for 6/20/2024
Earnings Highlights: AZO, LEN.B, LEN, KEP, FPS, TCOM, KR, Projections - See Details Inside! ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­
Earnings360 Home
Rickards Predicts: Trump to buy tiny $2 stock? (ad)
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the largest mineral reserve in the country - enough gold for a new Fort Knox, enough copper to rebuild the U.S. electric grid 25 times over.

The Trump administration has previously staked positions in MP Materials, Lithium America, Trilogy Metals, and USA Rare Earth - each time shares moved higher. A landmark policy decision expected before November 3 could reprice this stock from $2 to $20 or more within a year.
 
Click here to see why Rickards believes this stock is nexttc pixel
Top Earnings News
Campbell Soup Co. Targets Fiscal Q4 Stock Recovery
3 Strong Buy Stocks for a Sizzling Summer Rally
China Controls 80 Percent of Tungsten Supply Pentagon Reactstc pixel 
Adobe Stock Joined the A.I. Upswing with Impressive Gains

Thursday, June 20 Today's Earnings Announcements

CompanyCurrent PriceConsensus EPSActual EPSBeat/MissConsensus RevenueActual RevenueYoY Revenue GrowthReport
ACN Accenture$183.63$3.15$3.13($0.02)$16.47 thousand$16.55 thousand-.6%
CMC Commercial Metals$65.01$1.00$1.02$0.02$2.08 thousand$2.02 thousand-11.4%
DRI Darden Restaurants$213.30$2.61$2.65$0.04$3 thousand$2.97 thousand8.3%
FNB F.N.B.$17.65 - $0.40 - $419.30$0.00
JBL Jabil$308.33$1.85$1.89$0.04$6.77 thousand$6.53 thousand-20.2%
KR Kroger$58.57$1.33$1.43$0.10$45.27 thousand$44.86 thousand.2%
MASI Masimo$179.95 - $1.42 - $617.00$0.00
SCS Steelcase$16.11$0.10$0.16$0.06$727.30$729.05-3.3%
TEN Tsakos Energy Navigation$48.26$2.02$1.05($0.97)$159.57$0.00
NanoViricides Advances Ebola Drug Toward Phase II Trial in DRC (ad)
NNVC on Alert: FDA Validation and Outperform Rating!
NanoViricides (NYSE: NNVC) just cleared regulatory approval to begin a Phase II trial of NV-387 Oral Gummies for Ebola in the Democratic Republic of Congo, where the current outbreak has become the largest ever recorded.

Beyond Ebola, NV-387 is advancing for MPox and holds FDA Orphan Drug and Rare Pediatric Disease designations for Measles. Noble Capital Markets recently initiated coverage with an Outperform rating and a $6 price target.
 
See what could be next for this emerging antiviral story.tc pixel

Upcoming Earnings Reports

CompanyRelease DateRelease Time
CGBS Crown LNG1/1/2000Unknown
CHAA Catcha Investment1/1/2000Unknown
FDS FactSet Research Systems9/30/2026Morning
KMX CarMax9/29/2026Morning
MODD Modular Medical12/2/2026Unknown
YRD Yirendai11/25/2026Unknown
ASTL Algoma Steel Group11/4/2026Afternoon
EPAC Enerpac Tool Group10/21/2026Afternoon
HIVE HIVE Digital Technologies11/13/2026Unknown
NRSN NeuroSense Therapeutics12/2/2026Unknown
MNY MoneyHero12/4/2026Unknown
PBMLF Pacific Booker Minerals9/21/2026Unknown
PRGS Progress Software9/30/2026Unknown
SNX TD SYNNEX9/24/2026Unknown
FDX FedEx10/28/2026Afternoon
GHG GreenTree Hospitality Group11/25/2026Morning
CCL Carnival9/29/2026Morning
CUK Carnival6/23/2026Morning

MarketBeat Earnings Tools

Get Earnings Reports, Analysts' Forecasts, and Conference Call Transcripts.